Table 3.
Clinical trials providing information on tumour characteristics of patients with HCC who received TIPS
| Author | Enrolled patients with HCC + TIPS | Tumour size (cm) | Location | Single (1–2 lesions) |
Multiple (> 3 lesions) |
|---|---|---|---|---|---|
| Larrey E, et al. 2022 [6] | 8 | 1.2–4.9 |
Central: 1 Non-central: 7 |
8 | 0 |
| Yan H, et al. 2022 [18] | 123 | NA | NA | 42 | 81 |
| Qiu Z, et al. 2022 [15] | 42 | NA | NA | 9 | 33 |
| Dong H, et al. 2021 [12] | 13 | NA |
Central: 7 Non-central: 6 |
NA | NA |
| Tsauo J, et al. 2021 [17] | 126 | Max. 4.2 | NA | 98 | 28 |
| Bettinger D, et al. 2015 [14] | 40 | 1.6-8 |
Central: 15 Non-central: 25 |
21 | 19 |
| Liu L, et al. 2014 [13] | 58 | 2.6–16 | NA | 38 | 20 |
| Yao J, et al. 2015 [42] | 279 | Max. > 5 | NA | 270 | 9 |
| Qiu B, et al. 2015 [78] | 209 | Max. > 5 | NA | 148 | 61 |
HCC: hepatocellular carcinoma; TIPS: Transjugular intrahepatic portosystemic shunt; NA: not available